Biopharmaceutical start-up TwoXar has raised $200 million to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. The California -based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first -stage testing in years rather than weeks . The series A funding was led by SoftBank Ventures . Andrew Radin and OS Fund also took part. TwoXar CEO Andreessen Horowitz said the use of AI in pharmaceuticals had moved from speculation to practical application and would be a “major driver” of drug development.
Biopharmaceutical start-up TwoXar has raised $10m to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. The California-based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first-stage testing in weeks rather than years. The series A funding was led by SoftBank Ventures. Andreessen Horowitz and OS Fund also took part. TwoXar CEO Andrew Radin said the use of AI in pharmaceuticals had moved from speculation to practical application and would be a “major driver” of drug development.